FDA approves MannKind's FUROSCIX ReadyFlow Autoinjector?
Recent trades
18- 0x562b…dc09 BUY Yes $27.97 8h ago
- 0xd12f…e85a BUY Yes $164.84 10h ago
- 0xd12f…e85a BUY Yes $287.68 10h ago
- 0x4a74…7a5c SELL Yes $1.81 Jul 20
- 0x7a41…a18f BUY No $1.00 Jul 17
- 0x4a74…7a5c BUY Yes $2.00 Jul 16
- 0xd434…93bb BUY Yes $1.95 Jul 13
- 0x4b88…96a2 BUY Yes $1.89 Jul 11
- 0xf42f…a6a7 BUY Yes $88.54 Jul 4
- 0x3908…d10e SELL Yes $0.49 Jul 3
- 0xe215…1c22 BUY No $1.47 Jul 2
- 0x564f…7026 SELL Yes $15.12 Jul 2
- 0xf528…7e5b SELL Yes $4.80 Jul 2
- 0x3709…0e96 BUY No $1.38 Jul 1
- 0xf8fc…40bd SELL No $2.65 Jul 1
- 0x3908…d10e BUY Yes $1.00 Jul 1
- 0x564f…7026 BUY Yes $11.00 Jul 1
- 0x0096…de43 BUY Yes $53.71 Jul 1
As of market creation, the FDA's expected decision date for the specified application is July 26, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for MannKind's FUROSCIX ReadyFlow Autoinjector as a treatment for edema in adults with chronic heart failure or chronic kidney disease by August 9, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Comments